試す 金 - 無料
New Endometriosis Treatments Promise to Offer Relief
Mint Ahmedabad
|July 15, 2025
Doctors are rethinking ways to treat the chronic condition by using less-invasive diagnostic tools and surgeries
For decades, endometriosis, a chronic inflammatory condition that affects over 190 million women worldwide, got dismissed as "bad periods".
"Despite being as common as diabetes, it lacks a single definitive test and often takes more than seven years to diagnose," says Dr Anshumala Shukla Kulkarni, head of minimally invasive gynecology and robotic surgery at Kokilaben Dhirubhai Ambani Hospital in Mumbai. "Endometriosis is an estrogen-dependent inflammatory condition where endometrial-like tissue grows outside the uterus, most commonly on the ovaries, fallopian tubes, peritoneum, and, in severe cases, the bowel and bladder," explains Dr Sapna Raina, senior consultant at Narayana Health City, Bengaluru. "Yet despite its prevalence, the average diagnostic delay remains 7-10 years."
That delay, she adds, is not just a medical failure but a cultural one: "The hallmark symptom—chronic pelvic pain—is often dismissed as normal period pain, especially in adolescents and young women." The consequences? Women are frequently misdiagnosed with conditions like irritable bowel syndrome or urinary tract infections, while the root cause—endometriosis—goes untreated.
Now, thanks to a growing body of research, cutting-edge diagnostics, and a systemic push for recognition, endometriosis is no longer being relegated to the margins of women's health.
New research is challenging the necessity of invasive laparoscopies for diagnosis. Among the most promising innovations are mRNA-based blood and saliva tests, which can detect molecular changes invisible to conventional imaging.
このストーリーは、Mint Ahmedabad の July 15, 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Mint Ahmedabad からのその他のストーリー
Mint Ahmedabad
Bar on Prabhudas Lilladher stayed
The Securities Appellate Tribunal (SAT) has stayed an enquiry order issued by the Securities and Exchange Board of India (Sebi) that had barred Prabhudas Lilladher from taking on any new business for seven days over rule breaches.
1 min
December 12, 2025
Mint Ahmedabad
Big Pharma’s ‘patent cliff’ is a golden opportunity for China
Licensing pacts could help US drugmakers as their patents expire
3 mins
December 12, 2025
Mint Ahmedabad
Volltamp rally now hinges on growth beyond peak margins
Shares of Voltamp Transformers
1 mins
December 12, 2025
Mint Ahmedabad
Mexican tariffs to hit auto exports
including a manufacturing plant.
2 mins
December 12, 2025
Mint Ahmedabad
JPMorgan to open new branch in India
JPMorgan Chase & Co. is set to open a new branch in India after nearly a decade, underscoring the Wall Street bank’s growing push into one of the world’s fastest-growing economies.
1 min
December 12, 2025
Mint Ahmedabad
When realism and art meet
A Mint guide to what's happening in and around your city
1 min
December 12, 2025
Mint Ahmedabad
A shade that manifests the power of quiet
Pantone's annual pick of a colour of the year might be a marketing tool but a blank canvas seems like just what we need at the moment
2 mins
December 12, 2025
Mint Ahmedabad
Jeff Bezos and Elon Musk race to bring data centers to space
Space companies backed by tech billionaires hope to move AI data centers off Earth
3 mins
December 12, 2025
Mint Ahmedabad
For Donald Trump, the Warner megadeal talks are all about CNN
The fate of Warner Bros.
3 mins
December 12, 2025
Mint Ahmedabad
A carbon market offers benefits we should seize
While a robust carbon-pricing mechanism will take time, effort and capital to put in place, we can expect it to catalyse climate action and give India a chance to lead the Global South
2 mins
December 12, 2025
Listen
Translate
Change font size
